Clinical Trials List
Protocol NumberOBI-888-001
NCT Number(ClinicalTrials.gov Identfier)NCT03573544
2020-08-01 - 2022-08-31
Phase I/II
Not yet recruiting2
Recruiting1
A Phase I/II, Open Label, Dose Escalation and Cohort Expansion Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of OBI 888 in Patients with Locally Advanced or Metastatic Solid Tumors.
-
Trial Applicant
OBI PHARMA, INC.
-
Sponsor
OBI Pharma, Inc
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/20
Investigators and Locations
Co-Principal Investigator
- Ta-Chung Chao Division of Hematology & Oncology
- Mu-Hsin Chang Division of Hematology & Oncology
- Rheun-Chuan Lee Division of Hematology & Oncology
- Hao-Wei Teng Division of Hematology & Oncology
- Chueh-Chuan Yen Division of Hematology & Oncology
- 陳盛裕 Division of Hematology & Oncology
- San-Chi Chen Division of Hematology & Oncology
- Muh-Hwa Yang Division of Hematology & Oncology
- Ling-Ming Tseng Division of Hematology & Oncology
- Ming-Huang Chen Division of Hematology & Oncology
- Yi-Ping Hung Division of Hematology & Oncology
- Chung-Pin Li Division of Hematology & Oncology
- Sheng-Yu Chen Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- Chang-Fang Chiu Division of Hematology & Oncology
- Ming-Yu Lien Division of Hematology & Oncology
- Su-Peng Yeh Division of Hematology & Oncology
- Ching-Chan Lin Division of Hematology & Oncology
- Chen-Yuan Lin Division of Hematology & Oncology
- Ching Yun Hsieh Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- Shang-Yin Wu Division of Hematology & Oncology
- 趙盈瑞 Division of Hematology & Oncology
- 劉奕廷 Division of Hematology & Oncology
- Wen-Pin Su Division of Hematology & Oncology
- Yan-Shen Shan Division of Hematology & Oncology
- 顏志傑 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Metastatic Solid Tumors / Locally Advanced Solid Tumors
Objectives
The purpose of this study is to establish the maximum tolerated dose (MTD) of OBI-888 as monotherapy. And to characterize the safety and preliminary clinical activity profile of the MTD dose of OBI-888 administered as monotherapy in patients with locally advanced or metastatic solid tumors.
Test Drug
OBI 888
Active Ingredient
human recombinant IgG monoclonal antibody
Dosage Form
IV Injection
Dosage
150mg/5mL
Endpoints
Primary Outcome Measures:
1.Measurement of dose-limiting toxicities (DLTs).
2.Identification of a maximum tolerated dose of OBI-888.
Secondary Outcome Measures :
1.Measurement of preliminary clinical activity profile (objective response rate [ORR], clinical benefit rate [CBR], duration of response (DOR), and PFS) of OBI-888 in patients.
2.Measurement of the OBI-888 immunogenicity (anti-drug antibodies [ADAs]) in patients.
3.Pharmacokinetics (PK) - Maximum serum concentrations (Cmax) .
4.PK - total exposure Area Under Curve (AUC).
5.PK - elimination half-life (t1/2).
6.PK - clearance (Cl) .
7.PK - time to reach maximum concentration (Tmax).
8.PK - volume of distribution (Vd).
1.Measurement of dose-limiting toxicities (DLTs).
2.Identification of a maximum tolerated dose of OBI-888.
Secondary Outcome Measures :
1.Measurement of preliminary clinical activity profile (objective response rate [ORR], clinical benefit rate [CBR], duration of response (DOR), and PFS) of OBI-888 in patients.
2.Measurement of the OBI-888 immunogenicity (anti-drug antibodies [ADAs]) in patients.
3.Pharmacokinetics (PK) - Maximum serum concentrations (Cmax) .
4.PK - total exposure Area Under Curve (AUC).
5.PK - elimination half-life (t1/2).
6.PK - clearance (Cl) .
7.PK - time to reach maximum concentration (Tmax).
8.PK - volume of distribution (Vd).
Inclution Criteria
1.Male or female patients, 18 years of age or older at the time of consent.
2.Provide written informed consent prior to performing any study-related procedure.
3.Histologically or cytologically confirmed patients with advanced or metastatic solid tumors for both Dose Escalation and Expansion cohort.
4.Patients must have been treated with established standard-of-care therapy, or physicians have determined that such established therapy is not sufficiently efficacious, or patients have declined to receive standard-of-care therapy.
5.Measurable disease (i.e., at least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.
6.Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
7.Adequate organ function defined as:
--Hepatic:
1)Serum alanine aminotransferase (ALT) ≤3 × upper limit of normal (ULN), ≤5 × ULN in the presence of liver metastases
2)Serum aspartate aminotransferase (AST) ≤3 × ULN, ≤5 × ULN in presence of liver metastases
3)Serum bilirubin ≤1.5 × ULN
--Renal:
1)Creatinine clearance >30 mL/minute using Cockcroft Gault equation
--Hematologic:
1)Absolute neutrophil count ≥1000/µL
2)Platelets ≥75,000/µL
3)Hemoglobin ≥8 g/dL
8.Patient is willing and able to comply with all protocol required assessments, visits, and procedures, including pretreatment tumor biopsy. Archival tumor biopsies are acceptable at baseline.
9.Females of childbearing potential must have negative urine or serum pregnancy test prior to starting study therapy, and agree to use a reliable form of contraceptive during the study treatment period and for at least 120 days following the last dose of study drug.
Subject not of childbearing potential (i.e., permanently sterilized, postmenopausal) can be included in study. Postmenopausal is defined as 12 months with no menses without an alternative medical cause.
Male patients must agree to use an adequate method of contraception during the study treatment period and for at least 120 days following the last dose of study drug.
10.Cannot be breast feeding.
11.Patients in Part B (Cohort expansion); must have a qualifying, documented Globo H H-score in sponsor-selected tumor types to be enrolled in the respective cohort:
--Cohort 1: Pancreatic cancer
--Cohort 2: Esophageal cancer
--Cohort 3: Gastric cancer
--Cohort 4: Colorectal cancer
--Cohort 5: Basket (any solid tumor type other than those included in Cohorts 1 through 4)
2.Provide written informed consent prior to performing any study-related procedure.
3.Histologically or cytologically confirmed patients with advanced or metastatic solid tumors for both Dose Escalation and Expansion cohort.
4.Patients must have been treated with established standard-of-care therapy, or physicians have determined that such established therapy is not sufficiently efficacious, or patients have declined to receive standard-of-care therapy.
5.Measurable disease (i.e., at least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.
6.Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
7.Adequate organ function defined as:
--Hepatic:
1)Serum alanine aminotransferase (ALT) ≤3 × upper limit of normal (ULN), ≤5 × ULN in the presence of liver metastases
2)Serum aspartate aminotransferase (AST) ≤3 × ULN, ≤5 × ULN in presence of liver metastases
3)Serum bilirubin ≤1.5 × ULN
--Renal:
1)Creatinine clearance >30 mL/minute using Cockcroft Gault equation
--Hematologic:
1)Absolute neutrophil count ≥1000/µL
2)Platelets ≥75,000/µL
3)Hemoglobin ≥8 g/dL
8.Patient is willing and able to comply with all protocol required assessments, visits, and procedures, including pretreatment tumor biopsy. Archival tumor biopsies are acceptable at baseline.
9.Females of childbearing potential must have negative urine or serum pregnancy test prior to starting study therapy, and agree to use a reliable form of contraceptive during the study treatment period and for at least 120 days following the last dose of study drug.
Subject not of childbearing potential (i.e., permanently sterilized, postmenopausal) can be included in study. Postmenopausal is defined as 12 months with no menses without an alternative medical cause.
Male patients must agree to use an adequate method of contraception during the study treatment period and for at least 120 days following the last dose of study drug.
10.Cannot be breast feeding.
11.Patients in Part B (Cohort expansion); must have a qualifying, documented Globo H H-score in sponsor-selected tumor types to be enrolled in the respective cohort:
--Cohort 1: Pancreatic cancer
--Cohort 2: Esophageal cancer
--Cohort 3: Gastric cancer
--Cohort 4: Colorectal cancer
--Cohort 5: Basket (any solid tumor type other than those included in Cohorts 1 through 4)
Exclusion Criteria
1.Less than 3 weeks, from prior cytotoxic chemotherapy or radiation therapy; and less than 5 half-lives or 3 weeks from biological therapies, whichever is shorter, prior to the first dose of OBI-888.
2.Has undergone a major surgical procedure (as defined by the investigator) or significant traumatic injury within 28 days prior to the first dose of OBI-888.
3.Presence of an active autoimmune or inflammatory disease requiring systemic treatment within the past 2 months or a documented history of clinically severe autoimmune disease that requires systemic steroids or other immunosuppressive medications. Local steroid injections, intermittent use of topical, inhaled, ophthalmologic, intra-articular, topical, or intranasal corticosteroids, or systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or equivalent would not be excluded from the study.
4.Presence of primary immunodeficiency or receiving systemic steroids of >10 mg/day of prednisone or equivalent or other immunosuppressive agents within 14 days prior to the first dose of OBI 888.
5.Has active bacterial, viral, fungal, or mycobacterial infection requiring systemic therapy, including known infection with human immunodeficiency virus (HIV) or active infection with hepatitis B virus or hepatitis C virus.
6.Patients with a history of solid organ transplant.
7.Unresolved toxicities from prior anticancer therapy, defined as having not resolved to Grade 0 or 1 (using National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] version 4.03), except for alopecia and laboratory values listed in the inclusion criteria.
8.Receipt of any prior therapy targeting Globo H.
9.Known hypersensitivity to OBI 888 or its excipients.
10.Has known, untreated central nervous system metastases and/or leptomeningeal metastases.
11.Any medical co morbidity or psychiatric illness that is life threatening or, in the opinion of the Investigator, renders the patient unsuitable for participation in a clinical trial due to possible noncompliance, would place the patient at an unacceptable risk and/or potential to affect interpretation of results of the study.
12.Is receiving any concurrent prohibited medication.
2.Has undergone a major surgical procedure (as defined by the investigator) or significant traumatic injury within 28 days prior to the first dose of OBI-888.
3.Presence of an active autoimmune or inflammatory disease requiring systemic treatment within the past 2 months or a documented history of clinically severe autoimmune disease that requires systemic steroids or other immunosuppressive medications. Local steroid injections, intermittent use of topical, inhaled, ophthalmologic, intra-articular, topical, or intranasal corticosteroids, or systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or equivalent would not be excluded from the study.
4.Presence of primary immunodeficiency or receiving systemic steroids of >10 mg/day of prednisone or equivalent or other immunosuppressive agents within 14 days prior to the first dose of OBI 888.
5.Has active bacterial, viral, fungal, or mycobacterial infection requiring systemic therapy, including known infection with human immunodeficiency virus (HIV) or active infection with hepatitis B virus or hepatitis C virus.
6.Patients with a history of solid organ transplant.
7.Unresolved toxicities from prior anticancer therapy, defined as having not resolved to Grade 0 or 1 (using National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] version 4.03), except for alopecia and laboratory values listed in the inclusion criteria.
8.Receipt of any prior therapy targeting Globo H.
9.Known hypersensitivity to OBI 888 or its excipients.
10.Has known, untreated central nervous system metastases and/or leptomeningeal metastases.
11.Any medical co morbidity or psychiatric illness that is life threatening or, in the opinion of the Investigator, renders the patient unsuitable for participation in a clinical trial due to possible noncompliance, would place the patient at an unacceptable risk and/or potential to affect interpretation of results of the study.
12.Is receiving any concurrent prohibited medication.
The Estimated Number of Participants
-
Taiwan
16 participants
-
Global
150 participants
